143 related articles for article (PubMed ID: 22071539)
1. Axl of evil?
Aplin AE
J Invest Dermatol; 2011 Dec; 131(12):2343-5. PubMed ID: 22071539
[TBL] [Abstract][Full Text] [Related]
2. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
3. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
4. BRN2 and MITF together impact AXL expression in melanoma.
Simmons JL; Neuendorf HM; Boyle GM
Exp Dermatol; 2022 Jan; 31(1):89-93. PubMed ID: 33119145
[TBL] [Abstract][Full Text] [Related]
5. Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.
Fedorenko IV; Fang B; Koomen JM; Gibney GT; Smalley KS
Melanoma Res; 2014 Oct; 24(5):448-53. PubMed ID: 24950457
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.
Wang Y; Ou Z; Sun Y; Yeh S; Wang X; Long J; Chang C
Oncogene; 2017 Mar; 36(12):1644-1654. PubMed ID: 27869170
[TBL] [Abstract][Full Text] [Related]
7. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
[TBL] [Abstract][Full Text] [Related]
8. Investigating the utility of human melanoma cell lines as tumour models.
Vincent KM; Postovit LM
Oncotarget; 2017 Feb; 8(6):10498-10509. PubMed ID: 28060736
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
Tanaka M; Siemann DW
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576116
[TBL] [Abstract][Full Text] [Related]
10. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
Tworkoski KA; Platt JT; Bacchiocchi A; Bosenberg M; Boggon TJ; Stern DF
Pigment Cell Melanoma Res; 2013 Jul; 26(4):527-41. PubMed ID: 23617806
[TBL] [Abstract][Full Text] [Related]
11. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.
Sainaghi PP; Castello L; Bergamasco L; Galletti M; Bellosta P; Avanzi GC
J Cell Physiol; 2005 Jul; 204(1):36-44. PubMed ID: 15605394
[TBL] [Abstract][Full Text] [Related]
12. Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells.
Revach OY; Sandler O; Samuels Y; Geiger B
Cancer Res; 2019 May; 79(10):2634-2648. PubMed ID: 30914429
[TBL] [Abstract][Full Text] [Related]
13. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL.
Pietrobono S; Anichini G; Sala C; Manetti F; Almada LL; Pepe S; Carr RM; Paradise BD; Sarkaria JN; Davila JI; Tofani L; Battisti I; Arrigoni G; Ying L; Zhang C; Li H; Meves A; Fernandez-Zapico ME; Stecca B
Nat Commun; 2020 Nov; 11(1):5865. PubMed ID: 33203881
[TBL] [Abstract][Full Text] [Related]
14. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival.
van Ginkel PR; Gee RL; Shearer RL; Subramanian L; Walker TM; Albert DM; Meisner LF; Varnum BC; Polans AS
Cancer Res; 2004 Jan; 64(1):128-34. PubMed ID: 14729616
[TBL] [Abstract][Full Text] [Related]
15. AXL regulates mesothelioma proliferation and invasiveness.
Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
[TBL] [Abstract][Full Text] [Related]
16. Axl signaling induces development of natural killer cells in vitro and in vivo.
Kim EM; Lee EH; Lee HY; Choi HR; Ji KY; Kim SM; Kim KD; Kang HS
Protoplasma; 2017 Mar; 254(2):1091-1101. PubMed ID: 27549806
[TBL] [Abstract][Full Text] [Related]
17. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
[TBL] [Abstract][Full Text] [Related]
18. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
[TBL] [Abstract][Full Text] [Related]
20. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.
Avilla E; Guarino V; Visciano C; Liotti F; Svelto M; Krishnamoorthy G; Franco R; Melillo RM
Cancer Res; 2011 Mar; 71(5):1792-804. PubMed ID: 21343401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
